OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Child and Adolescent Psychopharmacology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Acknowledgment of Reviewers 2023	30
Letter to the Editor: Skin-Testing for Clones—Pediatric Obsessive Compulsive Disorder with Misidentification Syndrome	27
Description, Implementation, and Efficacy of the Comprehensive Behavioral Intervention for Tics as First-Line Treatment for Tourette and Other Tic Disorders	26
Pharmacological Treatment of Tourette Disorder in Children	25
Letter: Mirtazapine-Associated Hyperkinetic Movements in a 17-Year-Old with Autism Spectrum Disorder and Chronic Catatonia: A Case Report	22
Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications	19
Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis	19
Reducing Psychotropic Medication Use in Foster-Care Children with a Personalized Medication Review	18
From the Editor-in-Chief's Desk: Reflecting on Our Past and Future	17
Navigating Pharmacological Treatment in an Adolescent with New Onset Psychosis: Clinical, Pharmacological, and Cultural Challenges	17
A Randomized, Double-Blind, Controlled Trial of Lithium Versus Quetiapine for the Treatment of Acute Mania in Youth with Early Course Bipolar Disorder	16
Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES)	16
Incidence of Neuroleptic Malignant Syndrome During Antipsychotic Treatment in Children and Youth: A National Cohort Study	15
Monitoring of Adverse Drug Reaction-Related Parameters in Children, Youth, and Young Adults Prescribed Antipsychotic Drugs by General Practitioners	15
Response to Plöderl et al. re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder”	13
A Mobile Application Adjunct to Augment Cognitive–Behavioral Group Therapy for Adolescents with Social Anxiety: Feasibility and Acceptability Results from the Wiring Adolescents with Social Anxiety vi	13
From the Editor's Desk: Progress and Challenges for Psychiatric Phenotypes in Youth	13
From the Editor-in-Chief’s Desk: Long-Acting Injectable Antipsychotics	13
A Double-Blind Placebo-Controlled Pilot Study of Topiramate in Manic Adolescents Treated with Olanzapine	13
Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis	12
Short-Term Vision-Related Ocular Side Effects of Treatment with Dexmethylphenidate for Attention-Deficit/Hyperactivity Disorder	12
Letter to the Editor: Transition to In-Person School After Remote Learning—Mental Health Concerns in Youth with Developmental Disabilities	11
Psychotropic Medication Prescribing: Youth in Foster Care Compared with Other Medicaid Enrollees	10
Catatonia in a 16-Year-Old	10
Reported Side or Adverse Effects Associated with Medication Nonadherence Among Adolescents and Young Adults with Attention-Deficit/Hyperactivity Disorder	10

Letter: Improving Outcomes in Level 3 Autism after Treating Co-Occurring ADHD	10
Letter: Integrating Insights on Ketamine Efficacy and the Risk for Polydrug Use in Adolescents with Depression	10
Letter to the Editor: Olanzapine Treatment and Polyuria-Polydipsia in Two Children with Autism Spectrum Disorder	10
Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor	10
Combined Topiramate and Metformin Pharmacotherapy for Second-Generation Antipsychotic-Induced Weight Gain in Pediatric Bipolar Disorder and Aggression	9
Determining Clinically Meaningful Improvement in Children and Adolescents with Tourette Syndrome Receiving Pharmacotherapy	9
The Curious Case of Therapist Self-Disclosure During Pharmacotherapy Visits in an Autism Center	8
Pediatric Neuropsychiatric Syndromes: Updates on COVID-19 Infection and Vaccination	8
Letter to the Editor: Chlorpromazine-Induced Skin Pigmentation in a Pediatric Patient	8
A Counting Stroop Functional Magnetic Resonance Imaging Study on the Effects of ORADUR-Methylphenidate in Drug-Naive Children with Attention-Deficit/Hyperactivity Disorder	8
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study	8
From the Editor-in-Chief’s Desk: Maximizing Adherence, Digital Platforms, and Early Response for Precision Pediatric Psychopharmacology	8
Letter to the Editor: Suicide Risk Screening Practices in Youth with Developmental Disabilities	8
Association of Coexisting Conditions, Attention-Deficit/Hyperactivity Disorder Medication Choice, and Likelihood of Improvement in Preschool-Age Children: A Developmental Behavioral Pediatrics Researc	7
Letter to the Editor: The Impact of the COVID-19 Pandemic on the Mental Health of Youth with Developmental Disabilities	7
Can Neurocognitive Outcomes Assist Measurement-Based Care for Children with Attention-Deficit/Hyperactivity Disorder? A Systematic Review and Meta-Analyses of the Relationships Among the Changes in Ne	7
Psychiatric Polygenic Risk Scores and Week-by-Week Symptomatic Status in Youth with Bipolar Disorder: An Exploratory Study	7
Ketamine and Transcranial Magnetic Stimulation in an Adolescent with Treatment-Resistant Depression	7
Changes in Psychiatric Medication Use During the COVID-19 Pandemic in a Pediatric Long-Term Care Facility	7
Fluoxetine-Induced Serum Sickness-Like Reaction in an Adolescent with Obsessive Compulsive Disorder and Diabetes	6
A Preclinical Study of Standard Versus Accelerated Transcranial Magnetic Stimulation for Depression in Adolescents	6
The Safety and Clinical Effects of Amisulpride in Children and Adolescents with Psychiatric Disorders: A Case Series	6
Long-Term Improvement and Safety of Aripiprazole for Irritability and Adaptive Function in Asian Children and Adolescents with Autistic Disorder: A 52-Week, Multinational, Multicenter, Open-Label Stud	6
Rational Psychopharmacological and Psychotherapeutic Treatment of a 14-Year-Old Female with Functional Neurological Symptoms Disorder and Depression	6
Bowel and Bladder Dysfunction Is Associated with Psychiatric Comorbidities and Functional Impairment in Pediatric Obsessive-Compulsive Disorder	6
Vascular Endothelial Growth Factor Polymorphism rs699947 Is Associated with Neurostructural Phenotypes in Youth with Bipolar Disorder	6
Letter: Collaborating with Applied Behavior Analysis Teams to Optimize Telehealth Pharmacologic Management of Catatonia in Nonverbal Youth with Autism Spectrum Disorder	6
From the Editor-in-Chief's Desk	6
Correction to: A Predictive Biomarker Model Using Quantitative Electroencephalography in Adolescent Major Depressive Disorder, by McVoy, et al. J Child Adolesc Psychopharmacol 2022;32(9)	6
Response to Chadi A. Calarge re: “Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)”	6
Relative Age and the Use of Second-Generation Antipsychotics from 7 to 17 Years of Age: A Population-Based Register Study	6
A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder	5
Clinical Use of Clozapine Serum Level and Management of Adverse Effects in an Adolescent with Difficult to Treat Schizophrenia	5
Examining Whether Genetic Variants Moderate the Skeletal Effects of Selective Serotonin Reuptake Inhibitors in Older Adolescents and Young Adults	5
Pain in Tourette Syndrome: A Comprehensive Review	5
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Journal of Child and Adolescent Psychopharmacology	5
Letter to the Editor: Aripiprazole-Induced Hypersexuality in an Autistic Child	5
Neurocognitive Outcomes from Memantine: A Pilot, Double-Blind, Placebo-Controlled Trial in Children with Autism Spectrum Disorder	5
Efficacy of Preventing Relapse Evaluated by a Multicenter Randomized Double-Blind Placebo-Controlled Withdrawal Study of Escitalopram in Japanese Adolescents with Major Depressive Disorder	5
Association Between Single-Dose and Longer Term Clinical Response to Stimulants in Attention-Deficit/Hyperactivity Disorder: A Systematic Review of Randomized Controlled Trials	5
Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia	5
Correction to: A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder, by Strawn et al. J Child Adolesc Psychopha	5
Multivariable Prediction Modeling of Antidepressant Initiation in Unipolar Depressed Adolescents: A Secondary Analysis of the IMPACT Trial	5
Comparing Symptoms of Major Depression in Youth with Confirmed Versus Suspected Bipolar Disorder	5
Long-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder	5
Clonazepam Treatment of Adolescent Catatonia in A Setting of Lorazepam-Related Hypotension	5
From the Editor-in-Chief’s Desk: Gratitude for Mentors and Colleagues	5
Stimulant Patterns, Alone or with Other Psychotropic Classes, in Medicaid-Insured Youth Continuously Enrolled for 3–8 Years	4
A National Pediatric Telepsychiatry Curriculum for Graduate Medical Education and Continuing Medical Education	4
Prevalence and Factors Affecting the Use of Antipsychotics and Antipsychotic Polypharmacy in a Child and Adolescent Psychiatry Inpatient Service	4

Results from a Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Trial of Lovastatin or Minocycline in Fragile X Syndrome	4
Clinicians' Adherence to Guidelines When Initiating Methylphenidate Treatment	4
From the Editor-in-Chief's Desk: Advances in Patient-Centered Treatment for Attention-Deficit/Hyperactivity Disorder	4
Adherence to Clinical Guidelines for Dose Finding and Monitoring Methylphenidate Use: A Medical Record Audit in Child and Adolescent Mental Health Care and Pediatric Settings	4
A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder	4
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-	4
Relative Age Effect on Problematic Alcohol Use in Adolescents	4
Screening for Depression in Adolescents with Developmental Disabilities: Brief Report	4
Factors Associated with Symptom Persistence in PANS: Part II—Presenting Features, Medical Comorbidities, and IVIG Treatment History	4
From the Editor-in-Chief’s Desk: Special Issue on the Psychopharmacology of Neurodevelopmental Disorders	4
Evaluation of the Psychometric Properties of the Persian Version of Children's Depression Inventory in Iranian Adolescents	4
Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study	4
Trajectories and Predictors for the Development of Clinically Significant Weight Gain in Children and Adolescents Prescribed Second-Generation Antipsychotics	4
Correction to: The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives, by Klein	4